Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Ikerbasque, Fundación Vasca para la Ciencia
Bilbao, EspañaPublicaciones en colaboración con investigadores/as de Ikerbasque, Fundación Vasca para la Ciencia (61)
2024
-
Epigenetic-based differentiation therapy for Acute Myeloid Leukemia
Nature Communications, Vol. 15, Núm. 1
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
An engineered periosteum for efficient delivery of rhBMP-2 and mesenchymal progenitor cells during bone regeneration
npj Regenerative Medicine, Vol. 8, Núm. 1
-
Interactions between functional networks in Parkinson's disease mild cognitive impairment
Scientific Reports, Vol. 13, Núm. 1
2022
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease
Nature Reviews Neurology, Vol. 18, Núm. 4, pp. 203-220
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted
Journal of Hepatology, Vol. 75, Núm. 2, pp. 363-376
-
Functional correlates of response inhibition in impulse control disorders in Parkinson's disease
NeuroImage: Clinical, Vol. 32
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
O-GlcNAcylated p53 in the liver modulates hepatic glucose production
Nature Communications, Vol. 12, Núm. 1
-
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics
EBioMedicine, Vol. 73
2020
-
Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 2, pp. 437-450
-
Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats (Psychopharmacology, (2020), 237, 8, (2419-2431), 10.1007/s00213-020-05544-6)
Psychopharmacology
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders
Parkinsonism and Related Disorders, Vol. 70, pp. 74-81
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
-
Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease
Movement Disorders, Vol. 35, Núm. 2, pp. 316-325